Mouse Anti-Anti-HIV-1 antibody Recombinant Antibody (clone 1F7) (CAT#: HPAB-0005-YJ)

Figure 1 SHIV-IIIB-infected rhesus monkeys express 1F7 idiotope on anti-gp120 antibodies.

Plasma specimens from normal noninfected rhesus monkeys (control/1 and control/2) and SIV-infected rhesus monkey (SIV) together with serum from HIV-1-infected human (HIV) are shown in the first four column pairs. The following pairs show ELISA data from the four SHIV-infected rhesus monkeys selected for mAb vaccination. Anti-gp120 IIIB antibodies reacting with 1F7 (anti-IIIB/1F7, solid bars) and antibodies binding to recombinant gp120 IIIB (anti-IIIB, hatched bars) were detected in independent sandwich ELISAs. A replicate assay yielded similar results.

Müller, S., Margolin, D. H., Nara, P. L., Alvord, W. G., & Köhler, H. (1998). Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques. Proceedings of the National Academy of Sciences, 95(1), 276-281.

Figure 2 Sera from selected monkeys 441-92, 149-93, 337-91, and 42-93 were analyzed by ELISA for antibodies binding to gp120 IIIB and 1F7 expression.

Macaques 441-91, 149-93, and 331-91 displayed in A, B, and C were inoculated with mAb 1F7; macaque 42-93 was inoculated with isotype control mAb TEPC 183 (D). Prevaccination bleeds and sera from the peak response after vaccination are compared for each monkey. Determinations of triplicate ELISA readings are shown as mean and SD.

Müller, S., Margolin, D. H., Nara, P. L., Alvord, W. G., & Köhler, H. (1998). Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques. Proceedings of the National Academy of Sciences, 95(1), 276-281.

Figure 3 Effect of 1F7 or TEPC 183 injections on the neutralization response against HIV-1 IIIB in four macaques.

Data are shown for the four monkeys. Macaques 441-91, 149-93, and 337-91 displayed in A, B, and C were inoculated with mAb 1F7; macaque 42-93 was inoculated with isotype control mAb TEPC 183 (D). Selected time points (prebleed and days after the first mAb inoculation) are represented as serial serum dilutions (x axis) versus the reduction in the virus surviving fraction (V_n/V₀) on the y axis. The vertical bars indicate the standard error of the predicted means from the fitted regression curve (17).

Müller, S., Margolin, D. H., Nara, P. L., Alvord, W. G., & Köhler, H. (1998). Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques. Proceedings of the National Academy of Sciences, 95(1), 276-281.

Figure 4 Time-dependent effects of 1F7 mAb on IL-4 and IL-10 production by CD14⁺ monocytes and CD36⁺ lymphocytes.

PBMC from 10 healthy donors were incubated with 1.92 μg/ml 1F7 mAb or IgMκ mAb control for 24, 48 and 72 h and surface stained with anti-CD36 or anti-CD14. Cells were then fixed, permeabilized, incubated with anti-human IL-10, anti-IL-4 or isotype-matched controls and analyzed by flow cytometry for intracellular IL-10 (a) and IL-4 (b). Gating for intracellular cytokine analysis was done as shown in Figure 3. Data shown represent mean values ± SE.

Davtyan, T. K., Poghosyan, D. A., Sukiasyan, A. G., & Grant, M. D. (2013). The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance. Journal of Inflammation, 10(1), 14.

Figure 5 Influence of 1F7 mAb treatment on monocyte endotoxin tolerance.

Monocytes from 10 healthy donors were pre-treated with 100 ng/ml LPS or 1.92 μg/ml 1F7 mAb for 18 h, washed with LPS-free PBS and incubated for an additional 4 h with 1 μg/ml LPS or 1.92 μg/ml 1F7 mAb. Levels of TNF-α (a) and IL-10 (b) in supernatants were then measured. All data shown represent mean values ± SE. Significant differences by repeated ANOVA measures are noted between NT, LPS or 1F7 treatment (*p < 0.05) and between LPS re-stimulated pairs (#p < 0.05).

Davtyan, T. K., Poghosyan, D. A., Sukiasyan, A. G., & Grant, M. D. (2013). The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance. Journal of Inflammation, 10(1), 14.